Opus Genetics, Inc. (NASDAQ: IRD): Analyst Price Target and Upcoming Gene-Therapy Data

• Opus Genetics, Inc. (NASDAQ: IRD) is a clinical-stage biopharmaceutical company developing therapies for inherited retinal diseases and other eye disorders.
• H.C. Wainwright analyst Matthew Caufield reiterated a “Buy” rating and maintained an $8.00 price target for Opus Genetics in August 2026.
• The company plans to present topline Phase 1/2 Cohort 1 data for OPGx-BEST1 on September 9, 2026, providing an important clinical update for investors.

Opus Genetics, Inc. (NASDAQ: IRD) is a clinical-stage ophthalmic biopharmaceutical company. It develops gene therapies and other treatments intended to restore vision or prevent blindness in patients with inherited retinal diseases and other retinal disorders.

On August 10, 2026, H.C. Wainwright analyst Matthew Caufield reiterated a “Buy” rating on Opus Genetics and maintained an $8.00 price target. With the shares trading at approximately $4.67 on September 8, the $8.00 target implied potential upside of about 71%, although market prices can change throughout the trading session. 

The analyst’s rating comes ahead of an important clinical update. Opus Genetics plans to present topline data from Cohort 1 of its Phase 1/2 study of OPGx-BEST1 during an investor conference call and webcast on September 9, 2026, at 8:00 a.m. ET.

OPGx-BEST1 is an investigational gene therapy being developed for inherited retinal diseases caused by mutations in the BEST1 gene. The upcoming presentation will include three-month topline results from the first patient cohort. The company also plans to present the complete clinical dataset and additional analyses at upcoming medical conferences. 

Clinical results can significantly affect the valuation and share price of a development-stage biotechnology company. However, OPGx-BEST1 remains investigational, and favorable early-stage results would not guarantee success in later clinical trials or regulatory approval.